Alkem Laboratories Ltd
BSE:539523
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Alkem Laboratories Ltd
NSE:ALKEM
|
655.1B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
285.6B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
232.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
239.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Alkem Laboratories Ltd
Glance View
Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Alkem Laboratories Ltd is 16.6%, which is above its 3-year median of 14.5%.
Over the last 3 years, Alkem Laboratories Ltd’s Net Margin has increased from 9.1% to 16.6%. During this period, it reached a low of 8.5% on Mar 31, 2023 and a high of 17.2% on Jun 30, 2025.